Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?

Janine Astrid van Til, Maarten Joost IJzerman

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

Original language	English
Pages (from-to)	1-4
Journal	PharmacoEconomics
Volume	32
Issue number	1
DOIs	https://doi.org/10.1007/s40273-013-0118-6
Publication status	Published - 2014

Keywords

METIS-302381
IR-89396

Access to Document

10.1007/s40273-013-0118-6

Cite this

@article{dc6533002fec4ffcaf79664b1de7cddf,

title = "Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?",

keywords = "METIS-302381, IR-89396",

author = "{van Til}, {Janine Astrid} and IJzerman, {Maarten Joost}",

year = "2014",

doi = "10.1007/s40273-013-0118-6",

language = "English",

volume = "32",

pages = "1--4",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "1",

}

TY - JOUR

T1 - Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?

AU - van Til, Janine Astrid

AU - IJzerman, Maarten Joost

PY - 2014

Y1 - 2014

KW - METIS-302381

KW - IR-89396

U2 - 10.1007/s40273-013-0118-6

DO - 10.1007/s40273-013-0118-6

M3 - Article

SN - 1170-7690

VL - 32

SP - 1

EP - 4

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 1

ER -